TheEdgeResearch
Home / Stocks / IMMX

Immix Biopharma, Inc. (IMMX)

NASDAQ Healthcare Biotechnology
$6.96 ▼ -1.14%
Market Cap
$583.3M
Sector
Healthcare
Industry
Biotechnology
Beta
0.11
52-Wk Range
3.78-15.1
CEO
Ilya Rachman
Country
US
Currency
USD

Immix Biopharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $6.96, down 1.14% on the session, giving a market capitalisation of $583.3M. On trailing twelve-month figures it carries a trailing P/E of -8.39, a net margin of 0.0%. Its beta of 0.11 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-8.39
Price / Sales
0.00
Price / Book
1.54
EV / EBITDA
-5.68
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
33.72
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
21
IPO date
2021-12-16
Headquarters
Los Angeles, CA, US
About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

Comparable companies

Immix Biopharma, Inc. is most often compared with the following Healthcare names:

ABVXCLDXCRDFCTMXIMMPIMUXMGNXNBPNRIXRCUS
More research on IMMX
IMMX technical analysis IMMX TheEdge Score Compare against peers
Open full interactive analysis & DCF →